SynthesisBMC infectious diseases2026
Prevalence of latent tuberculosis infection in Malaysia: the first systematic review and meta-analysis.
Synthesis in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLatent tuberculosis infection (LTBI) remains a major public health challenge in Malaysia, yet prevalence estimates across population groups and settings are fragmented. This systematic review and meta-analysis aimed to synthesize available evidence and identify sources of heterogeneity.
methodsWe searched major databases for studies reporting LTBI prevalence in Malaysia. Random-effects meta-analyses were performed, with subgroup and meta-regression analyses to explore heterogeneity. Publication bias was assessed using Egger's and Begg's tests. Meta-analysis was performed using OpenMeta Analyst software and Comprehensive meta-analysis version 3.
resultsEighteen studies were included, yielding a pooled LTBI prevalence of 30.0% (95% CI; 18.7-44.4%). Marked variation was observed across states, populations, diagnostic tests, and settings. By state, prevalence ranged from 5.2% (95% CI: 4.0-6.7%) in Terengganu to 48.8% (95% CI: 1.8-98.0%) in Kelantan. By population group, the highest prevalence was recorded among people who are incarcerated (PWI) (83.0%, 95% CI: 65.3-92.7%), prison employees (81.0%, 95% CI: 76.9-84.4%), and contacts of multidrug-resistant TB patients (CMDR TB Patients) (52.7%, 95% CI: 41.4-63.8%), while lower rates were observed in Diabetes Mellitus patients (DMP) (10.2%, 95% CI: 3.7-24.8%), medical students (3.8%, 95% CI: 2.2-6.6%), and refugee children (12.8%, 95% CI: 10.0-16.3%). Diagnostic method was a significant source of heterogeneity: tuberculin skin test (TST) yielded higher prevalence (35.1%, 95% CI: 21.0-52.5%) than interferon gamma release assays (IGRA) (16.3%, 95% CI: 8.9-28.1%). By study setting, prisons showed the highest prevalence (82.4%, 95% CI: 71.4-89.8%), compared to hospitals (18.4%, 95% CI: 11.8-27.4%) and refugee schools (12.8%, 95% CI: 10.0-16.3%). Meta-regression confirmed states, diagnostic test, population groups, and setting as key sources of heterogeneity. Egger's (p = 0.4765) and Begg's tests (p = 0.9095) found no evidence of publication bias.
conclusionLTBI prevalence in Malaysia is high, particularly in prisons and high-risk occupational groups. Diagnostic method strongly influences estimates. Targeted screening, preventive therapy, and harmonization of diagnostic standards are essential for Malaysia's End TB strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.